Markers of bone remodeling in patients with surgical menopause undergoing hormone replacement therapy with Divigel

2021 ◽  
Vol 50 (3) ◽  
pp. 70-75
Author(s):  
S. V. Yureneva ◽  
V. P. Smetnik ◽  
N. V. Lyubimova ◽  
V. M. Abaev
Keyword(s):  
Alkaline Phosphatase ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Bone Tissue ◽  
Bone Remodeling ◽  
Hormone Replacement ◽  
Hormonal Replacement Therapy ◽  
Mineral Density ◽  
Hormonal Replacement ◽  
Surgical Menopause

Twenty women with surgical menopause, 40-50 years of age, received hormonal replacement therapy with transdermic preparation Divigel during 24 months. On the background of therapy with Divigel we witnessed normalization of indeces of osteal remodelingconsiderable decrease pyridinoline and deoxypyridinoline, and elevation of alkaline phosphatase. Mineral density of bone tissue in the group of patients with surgical menopause waslowerin comparison with control (p0,01). Divigeltumedto exertprotective influence on the bone tissue inpatients with osteoporosis irrespective о f duration о f surgical menopause by the beginning of therapy.

scholarly journals Overview on Hormonal Replacement Therapy in Menopause

2021 ◽  
pp. 141-147
Author(s):  
Shaden Akram A. Alanazi ◽  
Atheer Mansour E. Alatawi ◽  
Atheer Salman A. Alhwaiti ◽  
Aumniyat Saad A. Alrashidi ◽  
Ghadah Ali R. Alanazi ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Active Component ◽  
Hormone Replacement ◽  
Hormonal Replacement Therapy ◽  
Vasomotor Symptoms ◽  
Hormonal Replacement ◽  
Drug Classes ◽  
Menopausal Women ◽  
Pharmacological Studies

Hormone replacement therapy (HRT) is defined as a therapy that could allow women to free themselves from the malediction of estrogen loss and conserve their femininity. The study aims to summarize the updated evidence regards types, indication, contraindication, and untoward effects of hormonal replacement therapy among menopausal women. There are several different drug classes comprising estrogens, progestogens, and estrogen + progestogen combinations. Estrogen is the primary active component of HRT, treating menopausal symptoms, particularly vasomotor symptoms. There are several adverse effects of hormone replacement therapy that manifest in many different ways depending on the route of administration, and whether that route has local or systemic effects. Further research is needed to study the risks of menopausal HRT and pharmacological studies are needed to lower these risks and make its use safer with less side effects.

Mammography in women undergoing hormone replacement therapy

1997 ◽  
Vol 38 (2) ◽  
pp. 228-231 ◽  
Author(s):  
T. Rand ◽  
G. Heytmanek ◽  
M. Seifert ◽  
P. Wunderbaldinger ◽  
S. Kreuzer ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Hormonal Replacement Therapy ◽  
Cystic Lesions ◽  
Breast Parenchyma ◽  
Hormonal Replacement ◽  
Grade Scale ◽  
Malignant Lesions

Purpose: A retrospective study of screen-film mammographs was perfomed in 960 postmenopausal women to evaluate the possible effects of hormonal replacement therapy on the breast parenchymal pattern. Material and Methods: Screen-film mammographs of 754 women (mean age 51.4 years) who had undergone hormonal replacement therapy (estrogen, gestagen; mean duration 2.4 years) were compared with findings in 206 women who had not received hormonal replacement therapy (mean age 52.3 years). Mastopathic changes were analyzed according to a 4-grade scale and the incidence of circumscribed lesions (such as fibroadenomas, cysts and malignancies) was further evaluated. Results: in the treated women we found moderate mastopathic changes in 47.2%, intermediate changes in 2.4%, and extensive proliferations in 0.7%. for the untreated women the corresponding figures were 33.5%, 4.8%, and 1.4%. in the treated patients fibroadenomas were apparent in 3.9%, cystic lesions in 3.3%, and malignant lesions in 1.4%. in the untreated women fibroadenomas were evident in 11.6%, cystic lesions in 7.2%, and malignant lesions in 2.4%. Conclusion: Mastopathic changes might increase under hormonal replacement therapy. However, the higher incidence of circumscribed lesions in the untreated women might be due to the higher number of symptomatic women who sought examination. We also speculate as to whether the increased density of the breast parenchyma in the treated women might cause a higher number of mammographically undedectable lesions.

The state of estrogen-dependent organs of women with surgical menopause and hormone replacement therapy

2021 ◽  
Vol 50 (2) ◽  
pp. 94-99
Author(s):  
K. G. Serebrennikova ◽  
N. V. Chumakova ◽  
М. V. Konev
Keyword(s):  
Cardiovascular Disease ◽  
Hormone Replacement Therapy ◽  
Cardiovascular System ◽  
Replacement Therapy ◽  
Bone Tissue ◽  
Functional State ◽  
Hormone Replacement ◽  
Late Complications ◽  
Target Organs ◽  
Surgical Menopause

The research aims at studying the dynamics and character o f disorders in the target-organs and appraisingthe quality оf life in women with surgical menopause (SM ) on the background o f hormonal replacement therapy (HRT).Application o f Femoston as the preferable preparation was determined by functional state оf estrogen-dependent organs (cardiovascular system, bone tissue, and mamma) and accompanying extragenital diseases.Hormonal replacement therapy effectively reduces early climacterics disorders connected with menopause and promotes prophylaxis o f late complications o f menopause development (cardiovascular disease and osteoporosis). Femoston is the preparation o f choice fo r women with surgical menopause as it exerts minimum influence on the metabolism and doesnt have anabolic or glucocorticoid effects.

Concentration of selected micro-nutrients in saliva among women in menopausal period treated with hormone replacement therapy

2013 ◽  
Vol 22 (01) ◽  
pp. 46-51
Author(s):  
M. Rahnama ◽  
I. Jastrzêbska-Jamrogiewicz ◽  
R. Jamrogiewicz
Keyword(s):  
Bone Mineral Density ◽  
Hormone Replacement Therapy ◽  
Blood Serum ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Surgical Removal ◽  
Femoral Bone ◽  
Mineral Density ◽  
Natural Menopause ◽  
Copper Zinc

Summary Objective: The aim of this study was to observe the variability of the level of copper, zinc and manganese in saliva amongst women with hypoestrogenia, treated and untreated with hormone replacement therapy (HRT). Methods: The study was conducted on a group of 60 women treated and untreated with HRT. Half of the patients were after natural menopause and other half was after surgical removal of ovaries. Research on micronutrients in non-stimulated saliva and blood serum was carried out in 2005. Tests on saliva were repeated in 2010. Investigation of bone mineral density (BMD) of femoral bone was performed in year 2010. Results: Statistical analysis of concentration of copper and zinc revealed a linear correlation between the levels of these microelements in blood serum and saliva. The study revealed that HRT has a beneficial effect on BMD and the concentration of copper and manganese in saliva and blood serum of patients after the menopause. Patients treated with HRT showed higher BMD values than groups not treated with hormones. Conclusions: Saliva appears to be a promising diagnostic material which can be used to analyze the content of trace elements, but further research should be carried out on a broader research group.

scholarly journals Menarche in primary ovarian insufficiency after a month of hormone replacement therapy: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Biwen Cheng
Keyword(s):  
Replacement Therapy ◽  
Hormone Replacement ◽  
Estrogen Therapy ◽  
Primary Ovarian Insufficiency ◽  
Hormonal Replacement Therapy ◽  
Delayed Puberty ◽  
Ovarian Insufficiency ◽  
Breakthrough Bleeding ◽  
Hormonal Replacement ◽  
Ovarian Dysgenesis

Abstract Background Gynecologic anomalies, including uterine agenesis and ovarian dysgenesis, are some of the several differential diagnoses in adolescent females with primary amenorrhea and delayed puberty. Primary ovarian insufficiency is reported in the clinical practice of reproductive endocrinology can be determined by conducting sex hormone tests to evaluate the hypothalamic-pituitary-ovarian axis. However, confirmation of Mullerian agenesis by image modalities can be extremely challenging. Once the diagnosis is established, breakthrough bleeding usually occurs 2 to 3 years after hormonal replacement therapy. Case presentation We report a case of a seventeen year old Taiwanese female, 46 XX karyotype, with ovarian dysgenesis and an initial tentative diagnosis of uterine agenesis who experienced a breakthrough bleeding after a month of hormonal replacement therapy. Conclusions The breakthrough bleeding after a month of estrogen therapy in primary ovarian insufficiency is uncommon, and the diagnosis of the absent uterus can have an extensive psychological impact on patients and their families.

scholarly journals Nonassociation of Estrogen Receptor Genotypes with Bone Mineral Density and Estrogen Responsiveness to Hormone Replacement Therapy in Korean Postmenopausal Women

1997 ◽  
Vol 82 (4) ◽  
pp. 991-995 ◽  
Author(s):  
Ki Ok Han ◽  
In Gul Moon ◽  
Young Soon Kang ◽  
Ho Yeon Chung ◽  
Hun Ki Min ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Estrogen Receptor ◽  
Hormone Replacement Therapy ◽  
Lumbar Spine ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Gene Locus ◽  
Restriction Site ◽  
Hormone Replacement ◽  
Mineral Density

Abstract Hormone replacement therapy (HRT) prevents bone loss in postmenopausal women, but some women are resistant to therapy. A recently reported case of severe estrogen resistance caused by a germ-line mutation at the estrogen receptor (ER) gene locus suggests the possibility that other variants of the ER gene could be responsible for resistance to HRT and could also be an answer to the heritable components of bone density. Three restriction fragment length polymorphisms (RFLPs) at the ER gene locus, represented as BstUI (or B variant), PvuII, and XbaI, and their relationship to bone mineral density (BMD) and estrogen responsiveness to HRT were examined in 248 healthy postmenopausal women, aged 41–68 yr (mean± sd, 52.0 ± 4.6 yr) in Korea. The BstUI restriction site was not found in Korean women. The distribution of the PvuII and XbaI RFLPs was as follows: PP, 35 (14.1%); Pp, 136 (54.8%); pp, 77 (31.1%); and XX, 18 (7.3%); Xx, 72 (29.0%); and xx, 158 (63.7%), respectively (capital letters signify the absence of and lower case letters signify the presence of the restriction site of each RFLP). There was no significant relation between ER genotypes and z score values of lumbar spine BMD. Also, no significant genotypic differences were found in the change in lumbar spine BMD and those in biochemical markers before and after 1 yr of HRT. These data indicate no significant effects of ER genotypes on BMD and estrogen responsiveness after HRT.

Sign in / Sign up

Export Citation Format

Share Document